$ORKA stock has now risen 13% today, according to our price data from Polygon. There has been approximately $73,332,877 of trading volume.
It has been the 490th most-searched ticker on Quiver Quantitative over the last day, out of 13,208 total tickers searched.
Here is what we see in our data on $ORKA (you can track the company live on Quiver's $ORKA stock page):
$ORKA Insider Trading Activity
$ORKA insiders have traded $ORKA stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.
Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:
- CARL DAMBKOWSKI has made 0 purchases and 5 sales selling 140,000 shares for an estimated $8,645,748.
- JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 18 sales selling 43,588 shares for an estimated $2,208,194.
- ARJUN AGARWAL (Senior Vice President, Finance) has made 0 purchases and 9 sales selling 20,539 shares for an estimated $1,311,155.
- LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 13 sales selling 24,200 shares for an estimated $924,594.
- LAWRENCE OTTO KLEIN (Chief Executive Officer) has made 0 purchases and 2 sales selling 3,458 shares for an estimated $191,901.
- PAUL T QUINLAN (General Counsel) sold 733 shares for an estimated $51,082
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ORKA Hedge Fund Activity
We have seen 123 institutional investors add shares of $ORKA stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COMMODORE CAPITAL LP removed 1,753,054 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $85,987,298
- AVORO CAPITAL ADVISORS LLC removed 1,333,340 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $65,400,326
- BRAIDWELL LP removed 1,297,555 shares (-93.9%) from their portfolio in Q4 2025, for an estimated $39,328,892
- VANGUARD GROUP INC added 676,865 shares (+38.1%) to their portfolio in Q4 2025, for an estimated $20,515,778
- PARADIGM BIOCAPITAL ADVISORS LP added 610,000 shares (+35.7%) to their portfolio in Q1 2026, for an estimated $29,920,500
- POINT72 ASSET MANAGEMENT, L.P. removed 600,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $29,430,000
- BELLEVUE GROUP AG added 507,008 shares (+inf%) to their portfolio in Q1 2026, for an estimated $24,868,742
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ORKA Analyst Ratings
Wall Street analysts have issued reports on $ORKA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
To track analyst ratings and price targets for $ORKA, check out Quiver Quantitative's $ORKA forecast page.
$ORKA Price Targets
Multiple analysts have issued price targets for $ORKA recently. We have seen 8 analysts offer price targets for $ORKA in the last 6 months, with a median target of $110.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 05/18/2026
- Julian Harrison from BTIG set a target price of $151.0 on 05/14/2026
- Michael Yee from UBS set a target price of $100.0 on 04/28/2026
- Etzer Darout from Barclays set a target price of $160.0 on 04/28/2026
- Martin Fan from Wedbush set a target price of $85.0 on 04/15/2026
- Yatin Suneja from Guggenheim set a target price of $125.0 on 04/13/2026
- David Risinger from Leerink Partners set a target price of $86.0 on 03/16/2026
You can track data on $ORKA on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
